Oral Delivery of Large Molecules

About Us

Board of Directors 

Board of Directors

Mr. Gerald Lieberman - Chairman of the Board

Mr. Lieberman has served as a member of the Board of Directors since 2014. From 2000 until 2009, Mr. Lieberman was an executive at AllianceBernstein L.P. There, he was elected chief operating officer and a director in November 2003 and added the title of president in November 2004. Prior to that, Mr. Lieberman was senior vice president for finance and administration at Sanford C. Bernstein & Co., Inc. He has also held senior roles at Fidelity Investments and Citicorp. Mr. Lieberman currently serves on the board of Teva Pharmaceutical Industries Ltd. and serves as a special advisor at Reverence Capital Partners, a private investment firm focused on the middle-market financial services industry. Mr. Lieberman earned a B.S. from the University of Connecticut and attended New York University’s Graduate School of Business Administration. He is a certified public accountant, and a trustee of the University of Connecticut Foundation, Inc., where he is chairman of the finance committee and a member of the investment and executive committees.

Dr. Roger Garceau

Dr. Garceau has more than 30 years of broad pharmaceutical industry experience and has served as a director since March 2016 and as our Chief Development Advisor since December 2016. Prior to joining Entera, Dr. Garceau served as Chief Medical Officer and Executive Vice President of NPS Pharmaceuticals, Inc. since December 2008 and January 2013 respectively, until February 2015, when NPS Pharmaceuticals was acquired by Shire plc. Previously, Dr. Garceau has also served in several managerial positions with NPS Pharmaceuticals, Inc., Sanofi-aventis and Pharmacia Corporation. Dr Garceau has been a non-executive director of Enterome SA since December 2016. He is a board-certified pediatrician and is a Fellow of the American Academy of Pediatrics. Dr. Garceau holds B.S. in Biology from Fairfield University in Fairfield, Connecticut and an M.D. from the University of Massachusetts Medical School.

Miranda J. Toledano

Miranda J. Toledano is Chief Operating Officer and Chief Financial Officer at TRIGR Therapeutics, a clinical stage immuno-oncology company focused on bispecific antibodies. Ms. Toledano served on the executive management team of Sorrento Therapeutics (Nasdaq: SRNE) as EVP Corporate Development from September 2016 until August 2017. From 2012 to 2016, Ms. Toledano served as Head of Healthcare Investment Banking at MLV & Co. (acquired by B. Riley FBR & Co.), where she completed equity capital market transactions totalling over $4 billion in aggregate value. Prior to joining MLV, from 2004 until 2010, Ms. Toledano served in the investment group of Royalty Pharma, a leading investment firm with over $15 billion in biotherapeutic royalty assets. From 1998 to 2003, Ms. Toledano led the Life Sciences Corporate Finance group at Ernst & Young (Israel). Ms. Toledano holds a BA in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.

Mr. Ron Mayron

Mr. Mayron is global healthcare specialist who serves on the boards of numerous public and privately held pharma and medical device companies in Israel, including DNA BioMedical Solutions, Innocan Pharma, and IceCure Medical. His prior executive experience includes several leadership positions culminating in CEO of Teva Israel & Africa and CEO of S.L.E. His expertise within healthcare includes M&A, integration and implementation, global business development, global operations, and supply chain management. He earned a B.Sc. from Ben-Gurion University, an MBA from the University of Tel Aviv, and attended several programs at Insead University Fontainebleu, France and the Massachusetts Institute of Technology, Boston. Mr. Mayron served as an Officer in the Israeli army achieving the rank of Major.

Mr. Yonatan Malca

Mr. Malca has served as a member of the Board of Directors since 2011. Mr. Malca currently serves as a CEO and Director of D.N.A Biomedical Solutions Ltd., one of our principal shareholders, a position he has held since 2010. Mr. Malca also serves as a director of Arko Holdings Ltd., an Israeli public company. Mr. Malca also serves on the board of directors of a number of private companies, including as chairman of the board of directors of Cardioart Technologies LTD, a medical device company. Mr. Malca received a B.A. and an M.A. from Bar Ilan University.

Dr. Phillip Schwartz

Dr. Schwartz has more than twenty years of biotech and pharmaceutical industry experience. He has served as CEO and director of the board of director of Entera since its inception in September 2010. Previously he has held multiple positions in medical affairs, business development and clinical trial development at Serono and was served as manager of clinical affairs at Endo Pharmaceuticals. He has also consulted privately for more than 20 large biotech and pharmaceutical companies and a number of venture capital firms. Dr Schwartz has multiple publications in tier one peer reviewed journals and has presented papers at numerous international conferences. Dr. Schwartz completed his BA in psychology and architecture at Columbia University. He then studied and worked in neurobiology with Nobel Laureate Professor Torsten Wiesel of the Rockefeller University. After completing his project, Dr. Schwartz studied immunology with Professor Irun Cohen at the Weizmann Institute, receiving his MSc. in 1991. In 1997 Dr. Schwartz received his Ph.D. in neurobiology/development/oncology from Harvard Medical School.

Mr. Gerald M. Ostrov

Mr. Ostrov currently serves on the board of directors of several privately held companies, including Mother’s Choice, a natural products company working with industry giants, Addon Optics, an innovative technology company, and Nuvo, a developer of next generation baby and mother health monitoring for both hospital and home use. From 2008 to 2010, Mr. Ostrov served as Chairman and Chief Executive Officer of Bausch & Lomb Incorporated, where he helped to stabilize and restructure the business following its privatization. From 1998 to 2006, Mr. Ostrov served as Company Group Chairman for Johnson & Johnson's Worldwide Vision Care businesses. Mr. Ostrov began his career with Procter & Gamble He joined Johnson & Johnson's Health Care Division in 1976. In 1982, he left Johnson & Johnson and joined CIBA-Geigy. He was named President of Ciba Consumer Pharmaceuticals in 1985. He rejoined Johnson & Johnson in 1991 as President of the corporation's Personal Products Company. He was promoted to Company Group Chairman Consumer and Personal Care North America in 1994. Mr. Ostrov holds a Bachelor of Science degree with distinction in Industrial Engineering and Operations Research from Cornell University and holds an M.B.A. from Harvard University.